Fabino Life Sciences Ltd (FABINO) Fair Value & Analysis

Healthcare · IN · Market cap ₹42.7M

Below-average quality, and screening another 81% overvalued on our models.

What matters now

• The price sits above even our optimistic bull case (₹7.10). The favourable scenario is already priced in.
• Weak quality (41/100) and above fair value at the same time, the margin of safety is missing on both counts.
• The model range is unusually wide (₹0.7780 to ₹7.10). The outcome hinges heavily on assumptions, so read the point estimate with caution.
• The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Price vs Fair Value (5 years)

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 18, 2026.

How to read this chart

55‑month range ₹13.10 – ₹46.65 · fair‑value band ₹0.7780 – ₹7.10 · the ₹20.31 price screens above the ₹3.89 fair value. Dashed = 300-day average. As of Aug 18, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Fabino Life Sciences Ltd (FABINO) currently trades at ₹20.31, while our model-based Fair Value estimate is ₹3.89, implying the stock looks roughly 80.9% overvalued today. The Quality Score stands at 41/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).

Over the trailing twelve months, Fabino Life Sciences Ltd generated revenue of ₹208M at a net margin of -2.7%. Revenue grew 2.9% year over year. It earns a return on equity of -14.2%. Net debt stands at ₹14.3M. Fundamentals as of Aug 18, 2026

Our scenario range runs from ₹0.7780 (bear case) to ₹7.10 (bull case); at ₹20.31, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 28% below its 52-week high and 55% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -49% fair-value upside, at -81%, FABINO screens richer than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Widest divergence: Asset-Based (₹11.63) versus Multiples (₹3.89). Highest evidence: Growth DCF (80).

Key figures & financial health

Quality Score breakdown

About the company

Fabino Enterprises Limited, a pharmaceutical company, develops, manufactures, markets, trades in, and packages pharmaceutical and other wellness focused consumer products in India. The company offers allopathic, Covid-19, herbal, veterinary, and multi vitamin products, as well as food and wellness products under the Fabino and Keepshine brand names.

Full company description

Fabino Enterprises Limited, a pharmaceutical company, develops, manufactures, markets, trades in, and packages pharmaceutical and other wellness focused consumer products in India. The company offers allopathic, Covid-19, herbal, veterinary, and multi vitamin products, as well as food and wellness products under the Fabino and Keepshine brand names. It also exports wellness and FMCG products, such as coffee, malt powder, protein powder, hair shampoo, etc. The company markets its products through its own distribution network and sales force. The company was formerly known as Fabino Life Sciences Limited and changed its name to Fabino Enterprises Limited in June 2024. Fabino Enterprises Limited was incorporated in 2011 and is based in Sonipat, India.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2022 – FY2026 · reported fiscal years

Fabino Life Sciences Ltd reported revenue of ₹208M in FY2026 versus ₹42.0M in FY2022, a compound +49.2%/yr. Reported net income was −₹5.6M in FY2026.

FABINO screens 81% overvalued. Compare with Jiangsu Hengrui Pharmaceuticals Co →

Peer Group

Drug Manufacturers - Specialty & Generic · 633 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Valuation Multiples vs Drug Manufacturers - Specialty & Generic median · lower = cheaper

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 0: the price sits above our fair-value range.

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Aug 18, 2026).

Explore undervalued stocks

More undervalued Healthcare stocks →

Frequently asked questions

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.